Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program with Investment from Gurnet Point Capital
Posted on 377 Tremeau Pharmaceuticals announced today that Gurnet Point Capital has agreed to fund the clinical development of its investigational drug TRM-201 (rofecoxib), including a Phase III trial of TRM-201 for hemophilic arthropathy (HA). Gurnet Point Capital, a private investment firm focused on the healthcare and life sciences sectors, is Tremeau’s primary investor. HA is a painful and degenerative joint disease caused by recurrent intra-articular bleeding in patients with inheritable bleeding disorders. Although HA is th...
Source: financialbuzz.com